Company Presentation – EGM April 2024

RAD

RADIOPHARM THERANOSTICS

IMPORTANT NOTICE AND DISCLAIMER

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation is not a prospectus or other disclosure document under the *Corporations Act 2001* (Cth) and will not be lodged with the Australian Securities and Investments Commission. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this presentation, you should observe such restrictions as any non-compliance with these restrictions could contravene applicable securities laws (see the section captioned ‘International offer restrictions’). In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change.

RAD IS AT THE CUTTING EDGE OF RADIOPHARMACEUTICALS, A TRANSFORMATIVE MODALITY WITHIN CANCER

Differentiated Within Radiopharmaceuticals

- Clinical-stage company with deep pipeline of radiotherapy assets pursuing novel targets within radiotherapy, leveraging insights from ADCs, using elegant targeting moieties such as nanobodies
  - Targets include integrin αVβ6 , PDL-1, fatty acid synthase, HER2, B7H3 and TROP2
  - Some being interrogated in indications where precedent molecules have not known to be focused or exploiting novel MoAs

Radiopharmaceuticals Expertise

- All team members with previous imaging and therapeutic radiopharmaceutical experience
- Extensive Scientific Advisory Board of accredited multinational researchers

Radiopharm Ventures, a Joint Venture with MD Anderson Cancer Center

- JV (private company) in-licensed from MDACC technologies for radiopharmaceuticals use
- First technology has been disclosed (B7H3-targeting molecule)
- Separate investment opportunity to enter JV with a significant position (currently RAD at 51%, MDACC at 49%)

In licensing Strategy & Intellectual Property

- Proprietary molecules designed to identify and target a broad range of malignancies, in solid tumors.
- Extensive patent portfolio for targets through 2040

COMPANY PIPELINE

PROGRAM	TARGET & MOLECULE	INDICATION	Dx/Tx	ISOTOPE	PRECLINICAL	PHASE I	PHASE II	NOTES
RAD204	PDL-1 (Nanobody)	NON-SMALL CELL LUNG CANCER	Therapy	Lu177		***		Phase 1** enrolling in Australia
RAD301	Integrin $\alpha V\beta 6$ (Peptide)	PANCREATIC CANCER	Imaging	Ga68		***		FDA Orphan Drug Designation Phase 1* enrolling in the US
RAD302			Therapy	Lu177				Preclinical package to be completed by 2024 Phase 1 trial planned in early 2025
RAD101	Fatty Acid Synthase (Small Molecule)	BRAIN METS	Imaging	F18		Phase 2a ***	Phase 2b	IND preparation for Phase 2b in US (n=30)
RAD102			Therapy	I123				R&D stage Candidate selection ongoing at Imperial College of London
RAD202	★HER 2 (Nanobody)	BREAST / GASTRIC CANCER	Therapy	Lu177				Preclinical & CMC completed Phase 1 trial planned in late 2024
RV01	★★B7H3 (mAb)	PROSTATE, LIVER PANCREAS, COLON	Therapy	Lu177				From Joint Ventures MD Anderson-RAD CMC production ongoing Preclinical package to be completed in late 2024
Additional Preclinical Programs	★KLK3 (mAb) ★LRRC15 (mAb) ★TROP2 (Nanobody)	Prostate Osteosarcoma TNBC/ NSCLC	Therapy	Tb161 Tb161 Ac225				

RADIOPHARM VENTURES

* NCT05799274 **ACTRN12623000959673 ***Denotes clinical priorities. ★ ADC targets. ★ Novel prostate targets.

BETABART®: First and only B7-H3 radiopharmaceutical in development



BETABART®

Isoform-Selective Targeting of 4Ig-B7-H3 for PET Imaging and Beta-Radioligand Therapy

B7-H3 (CD276) IS AN EXQUISITE TUMOR-SPECIFIC TARGET

- Conserved member of the B7 family
- B7-H3 protein is highly expressed in many common aggressive tumors and is not expressed or not accessible in normal tissues
- B7-H3 expression on tumor-associated vascular and “immune-suppressive” immune infiltrate

BETABART HAS HIGH AFFINITY AND SELECTIVITY FOR 4IG-B7-H3 ISOFORM

- The 4Ig-B7-H3 isoform is the dominant isoform in human cancers
- A soluble 2Ig-B7-H3 isoform circulating in the blood is a potential pseudo-target decoy; Betabart has demonstrated favorable affinity ratio for 4Ig:2Ig in preclinical models

BETABART®: 56% Increased Survival with single dose injection



(* p = 0.0376, log-rank test)
(** p = 0.0034, log-rank test)
(*** p = 0.003, log-rank test)

CT26 4Ig-B7-H3 Tumors



Preclinical study performed at MD Anderson

CLINICAL DEVELOPMENT & REGULATORY STRATEGY

- Preclinical models validated selective targeting of tumor cells
- Significant tumor reduction and increased survival in animal model
- GMP CMC production ongoing. GMP batch in Q3 2024
- GLP TOX and Biodistribution studies in Q3 –Q4 2024
- Phase I trial in the first half of 2025

Preclinical	PHASE I
	Basket trial in multiple indications
CMC GMP, GLP Tox, BioD	25 pts
completed by end 2024	Opening in first half 2025

CONTACT US

Riccardo Canevari

CEO & MANAGING DIRECTOR

Radiopharm Theranostics Limited
T +1 862 309 0293

E rc@radiopharmtheranostic.com

W www.radiopharmtheranostics.com

Paul Hopper

Executive Chairman

Radiopharm Theranostics Limited
T +61 406 671 515

E paulhopper@lifescienceportfolio.com

W www.radiopharmtheranostics.com